Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9050850 | 1.00 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL2369243 | 1.00 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL960818 | 1.00 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL26962278 | 1.00 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL100090 | 1.00 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL8480025 | 1.00 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL9051516 | 1.00 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL19153077 | 0.98 | CA14 (0.41) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL3882477 | 0.92 | HDAC6 (0.39) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL99172 | 0.91 | HDAC1 (0.37) | HDAC6HDAC1HDAC2CA14L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654878-B2 | Compounds of phosphinanes and azaphosphinanes, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2020-05-19 | — | — | US | disclosed |
| US-20190031693-A1 | COMPOUNDS OF PHOSPHINANES AND AZAPHOSPHINANES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2019-01-31 | — | — | US | disclosed |
| US-20180016288-A1 | COMPOUNDS OF PHOSPHINANES AND AZAPHOSPHINANES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2018-01-18 | — | — | US | disclosed |
| US-20180016288-A1 | COMPOUNDS OF PHOSPHINANES AND AZAPHOSPHINANES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2018-01-18 | — | — | US | disclosed |
| WO-2017121969-A1 | NOVEL PHOSPHINANE AND AZAPHOSPHINANE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2017-07-20 | — | — | WO | disclosed |
| US-7208515-B2 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20070032524-A1 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2007-02-08 | — | — | US | disclosed |
| US-7151115-B2 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2006-12-19 | — | — | US | disclosed |
| EP-1725525-A1 | DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2006-11-29 | — | — | EP | disclosed |
| US-7071224-B2 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20060122182-A1 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2006-06-08 | — | — | US | disclosed |
| WO-2005087722-A9 | DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE INC (US) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005087722-A1 | DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20050203161-A1 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654878-B2 | Compounds of phosphinanes and azaphosphinanes, a process for their preparation and pharmaceutical compositions containing them | TK1, AK1, PHKA1 | HDAC6 2522/4885HDAC1 1281/4885HDAC2 1839/4885 |
| US-20060122182-A1 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM5 | HDAC6 3713/4885HDAC1 2521/4885HDAC2 2575/4885 |
| US-20070032524-A1 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM5 | HDAC6 3713/4885HDAC1 2521/4885HDAC2 2575/4885 |
| US-20050203161-A1 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | HDAC6 3723/4885HDAC1 2520/4885HDAC2 2630/4885 |
| US-20180016288-A1 | COMPOUNDS OF PHOSPHINANES AND AZAPHOSPHINANES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TK1, AK1, PHKA1 | HDAC6 2522/4885HDAC1 1281/4885HDAC2 1839/4885 |
| US-20190031693-A1 | COMPOUNDS OF PHOSPHINANES AND AZAPHOSPHINANES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AK1, TK1, PHKA1 | HDAC6 2473/4885HDAC1 1361/4885HDAC2 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.